SIENNA DEVELOPS PAN-CANCER TEST
February 2nd 2008 07:02
SIENNA DEVELOPS PAN-CANCER TEST
* ASX UP, BIOTECHS EVEN: OPTISCAN UP 18%, GENETIC DOWN 10%
* SIENNA DEVELOPS PAN-CANCER TEST
* USCOM SAYS LONDON ICU STUDY BACKS MONITOR
* ROCKEBY WINS BIRD FLU CONTRACT WITH UNNAMED ASIAN NATION
* NEUREN RIGHTS ISSUE RAISES 7.1m
* NORWOOD ABBEY SPINS-OUT MIT NEEDLE-FREE TECHNOLOGY
* AUSTRADE TELLS BIOTECHS TO LOOK TO JAPAN
* SOLAGRAN IN PROPOSED ALLIANCE WITH MENARINI GROUP
* BIOSECURITY CONFERENCE IN BRISBANE
THE MARKET
Twelve of the Biotech Daily Top 40 stocks were up, 11 fell, 12 traded unchanged and five were untraded.
Optiscan was best, up 4.5 cents or 18.0 percent to 29.5 cents with 9,716 shares traded.
Genetic Technologies led the falls, down 1.5 cents or 10.34 percent to 13 cents on moderate volumes, followed by Chemgenex down seven cents or 8.24 percent to 78 cents.
subscribe to Biotech Daily at the link above
SIENNA CANCER DIAGNOSTICS
Melbourne’s Sienna Cancer Diagnostics will use technology licenced from California's Geron Corp to develop and commercialize cancer diagnostic tests based on its telomerase biosensing technology (TBT).
Sienna said telomerase enzyme has “great potential as a cancer biomarker, being present in about 95 percent of all epithelial cancers” including bladder, kidney, prostate, stomach, lung, ovarian and colorectal cancers and is one of the only pan-cancer biomarkers recognized worldwide.
Sienna said the telomerase enzyme maintains telomere length at the ends of chromosomes. This activity confers replicative immortality to the cells in the tumor, allowing the cancer to grow and metastasize over long periods of time. Because telomerase is inactive or only transiently expressed in normal human tissues and is critical to the growth and progression of most cancer types, it is regarded as a universal and specific cancer target.
Sienna said that to date, no other established biomarker, such as prostate specific antigen (PSA) or CA-125 for ovarian cancer, has been shown to be expressed across such a range of cancers, making telomerase one of the only accepted pan-cancer biomarkers.
Sienna’s lead product in development is a non-invasive assay using its proprietary telomerase biosensor technology to detect telomerase activity in urine for the diagnosis of bladder cancer.
The assay could supplement or replace invasive cystoscopy procedures. The US spends $US700 million a year on cystoscopic procedures to monitor and diagnose bladder cancer.
Under the licence, Sienna gains worldwide exclusive rights within a defined field to Geron-controlled intellectual property to detect telomerase activity for the cancer in vitro diagnostics market.
In payment, Geron received “a significant equity interest in Sienna and is entitled to receive royalties on future product sales”.
Sienna’s TBT test is a highly sensitive, non-invasive test for the detection of cancer using bodily fluids such as urine, blood or faeces.
Sienna’s technology will enable the detection and monitoring of a range of cancers using inexpensive, rapid, non-invasive techniques.
Sienna has co-developed its two technological platforms in collaboration with the Ludwig Institute for Cancer Research, the world’s largest cancer research institution.
Sienna said clinical trials suggested its test has potential application in the management of bladder cancer.
Sienna said bladder cancer was its first target disease because it was costly and had the highest rate of recurrence of any malignancy.
Cystoscopy is an invasive, subjective and costly procedure, which could be supplemented or replaced by Sienna’s non-invasive test.
Sienna said its clinical and non-clinical studies were expected to result in submissions to US and European regulatory bodies and in commercialization of the test.
Sienna said it had taken its cancer in vitro diagnostics technologies from start-up to early-stage commercialization, with first product delivery expected within 24 months.
Sienna said Geron was “the world leader in the development of human embryonic stem cell-based therapeutics”, with its spinal cord injury treatment expected to be the first product to enter clinical development.
Sienna is a public unlisted company and expects to list on the ASX later this year.
www.siennadiagnostics.com.au.
Subscribe to Biotech Daily at the link above
Biotech Daily
Thursday January 31, 2008
Daily news on ASX-listed biotechnology companies
Thursday January 31, 2008
Daily news on ASX-listed biotechnology companies
* ASX UP, BIOTECHS EVEN: OPTISCAN UP 18%, GENETIC DOWN 10%
* SIENNA DEVELOPS PAN-CANCER TEST
* USCOM SAYS LONDON ICU STUDY BACKS MONITOR
* ROCKEBY WINS BIRD FLU CONTRACT WITH UNNAMED ASIAN NATION
* NEUREN RIGHTS ISSUE RAISES 7.1m
* NORWOOD ABBEY SPINS-OUT MIT NEEDLE-FREE TECHNOLOGY
* AUSTRADE TELLS BIOTECHS TO LOOK TO JAPAN
* SOLAGRAN IN PROPOSED ALLIANCE WITH MENARINI GROUP
* BIOSECURITY CONFERENCE IN BRISBANE
THE MARKET
Twelve of the Biotech Daily Top 40 stocks were up, 11 fell, 12 traded unchanged and five were untraded.
Optiscan was best, up 4.5 cents or 18.0 percent to 29.5 cents with 9,716 shares traded.
Genetic Technologies led the falls, down 1.5 cents or 10.34 percent to 13 cents on moderate volumes, followed by Chemgenex down seven cents or 8.24 percent to 78 cents.
subscribe to Biotech Daily at the link above
SIENNA CANCER DIAGNOSTICS
Melbourne’s Sienna Cancer Diagnostics will use technology licenced from California's Geron Corp to develop and commercialize cancer diagnostic tests based on its telomerase biosensing technology (TBT).
Sienna said telomerase enzyme has “great potential as a cancer biomarker, being present in about 95 percent of all epithelial cancers” including bladder, kidney, prostate, stomach, lung, ovarian and colorectal cancers and is one of the only pan-cancer biomarkers recognized worldwide.
Sienna said the telomerase enzyme maintains telomere length at the ends of chromosomes. This activity confers replicative immortality to the cells in the tumor, allowing the cancer to grow and metastasize over long periods of time. Because telomerase is inactive or only transiently expressed in normal human tissues and is critical to the growth and progression of most cancer types, it is regarded as a universal and specific cancer target.
Sienna said that to date, no other established biomarker, such as prostate specific antigen (PSA) or CA-125 for ovarian cancer, has been shown to be expressed across such a range of cancers, making telomerase one of the only accepted pan-cancer biomarkers.
Sienna’s lead product in development is a non-invasive assay using its proprietary telomerase biosensor technology to detect telomerase activity in urine for the diagnosis of bladder cancer.
The assay could supplement or replace invasive cystoscopy procedures. The US spends $US700 million a year on cystoscopic procedures to monitor and diagnose bladder cancer.
Under the licence, Sienna gains worldwide exclusive rights within a defined field to Geron-controlled intellectual property to detect telomerase activity for the cancer in vitro diagnostics market.
In payment, Geron received “a significant equity interest in Sienna and is entitled to receive royalties on future product sales”.
Sienna’s TBT test is a highly sensitive, non-invasive test for the detection of cancer using bodily fluids such as urine, blood or faeces.
Sienna’s technology will enable the detection and monitoring of a range of cancers using inexpensive, rapid, non-invasive techniques.
Sienna has co-developed its two technological platforms in collaboration with the Ludwig Institute for Cancer Research, the world’s largest cancer research institution.
Sienna said clinical trials suggested its test has potential application in the management of bladder cancer.
Sienna said bladder cancer was its first target disease because it was costly and had the highest rate of recurrence of any malignancy.
Cystoscopy is an invasive, subjective and costly procedure, which could be supplemented or replaced by Sienna’s non-invasive test.
Sienna said its clinical and non-clinical studies were expected to result in submissions to US and European regulatory bodies and in commercialization of the test.
Sienna said it had taken its cancer in vitro diagnostics technologies from start-up to early-stage commercialization, with first product delivery expected within 24 months.
Sienna said Geron was “the world leader in the development of human embryonic stem cell-based therapeutics”, with its spinal cord injury treatment expected to be the first product to enter clinical development.
Sienna is a public unlisted company and expects to list on the ASX later this year.
www.siennadiagnostics.com.au.
Subscribe to Biotech Daily at the link above
| 69 |
| Vote |
Add To: 
subscribe to this blog